- NewsCategory：
- All Company news Industry news
common83One result
-
1226
Bank of England Enhances Scr≠₩utiny of Lloyd’s Whistleblower Systems
The Bank of England has ±☆stepped up its monitori♥✔★ng of Lloyd’s of Lo>€γ$ndon’s whistleblowing systems, the π•♠central bank said on Monday, ™∏≤after reports this year↔♠ about sexual har>£≤assment and bullying ÷∑®at the 330-year old insurance mark₽✘←✘et.The Prudential Regulation Authority (P←δ§RA) said the insurance market$× had agreed to extra checks after in☆Ω₩&forming the regulator its p☆φrocesses had been ineffective.he PR↔π≥πA said it was first mα↕ade aware of issues a≠≥ασt Lloyd’s in February when the marke★π₽t told the regulator its only an★♥∏onymous whistleblowing channel for sta® ff had not been operational since Octo"'§ber 2017.Other whist"♠©→leblowing channels were available w₽↓×hile the anonymous hotline was ∏÷down, the PRA said.Lloyd’s also failed ™₽®to provide an annualφ ± whistleblowing report as expected, the regula×±₩tor added.Lloyd’s has voluntaril∞λεy agreed to additional requirements,απ★© including enhanced reporting of wφ•histleblowing cases and training ↑← requirements for senior staff, ♥§the PRA said.Following press reports of widesprβ↔β★ead misconduct at Lloyd’s<♠←, the market published results of a survey '₽₽←in September that found n≤₽>early one in 12 employees working in the market h♣Ωad witnessed sexual harassε≠ment there in the past year, whiΩδle a quarter had witn♦★essed excessive drinking.Lloyd’s hπ as tried to improve standards of behavio♣≤π♣r in the market ♥₽₩this year, including introducing li±♣¥λfe bans from its buildוing and a bullying and haras€¶£≥sment hotline.The Lloyd’sλ× market employs nearly 50,000 people a®≈♦€nd has 99 syndicate members offeβαring insurance ±¥←in specialist areas from ships>∑α to sculptures.“We are extremely disappointeλ↕≈d by this failure in ou↓∏r internal controls, which serves t ♥o remind us all about the need for constant∏☆♣& vigilance when it comes to the≥δse essential services,” a Lloyd’s spokesman said.₽♥∑<“Lloyd’s employees can feel confident that we ×'now have all the right mechanisms in p&±lace for them to rep§δ÷ ort any wrongdoing, and¥×∑β that these systems are regularly monitore'∞€↑d.”(Reporting by Iai↕δn Withers; editing by Louise Heavens and©∑ Edmund Blair)From:insurance journalOrg䮥anizer：China Insurance Digital & AI D¶☆'✔evelopment 2020Web:http://en.zenseegro€↑&₩up.com/p/560573/Contact:Ann 021-65650305 -
0822
Tonix Pharmaceuticals Expand'★s Preclinical Pipeline with Triple Reuptak>♥γ e Inhibitor, TNX-1600, fo↔★∑↕r the Treatment of PTSD
Tonix Pharmaceuticals HoldiΩ✔ng Corp., a clinical-stage biopharmac♦↔β☆eutical company, announced today an excl↔£γusive agreement to in-license a triple reupt≠ake inhibitor (TRI), TNX-1600 ££↔✘(formerly D-578), to treat postt✘♣♠πraumatic stress disorder (PTSD) and potentλ¶Ω∞ially other central nervous system (CNS) disorde¥' <rs. The compound was d∞"✔eveloped and pharmacologically ch₽←aracterized by Aloke D¥✔γutta, Ph.D., professor of¶®®β Pharmaceutical Sciences at Wayne State Uni♠÷versity, with funding from a National Institut✘es of Health grant (grant nu™↑mber MH084888), and the paten$€ts covering the compounds were±Ω≤ licensed to TRImaran Pharma, Inc. (TRI±®maran). The transaction announ≈ ♥≤ced today is a license agre₽© ↕ement with Wayne State and an asset a™♦♣'cquisition with TRImaran.“We are excited ×Ω↔to expand our pipeline and are looking forwa↕✔rd to developing TNX-1600 a✔±★s a potential treatment for PTSD,” said Set€®✘h Lederman, M.D., Tonix€★'s President and Chief Exec®Ωutive Officer. “We p α≥lan to utilize our clinical experience in↓≈$↕ PTSD to evaluate the therapeutic benefit of TN↑&X-1600. PTSD is a het δerogeneous condition, so we believe differe☆λ✔'nt PTSD patients may respond to different m≠™♣edicines. In some cases, more th σΩan one drug will be required for effective tr∑€β¶eatment. TNX-1600 is ou<₽♣r third drug candida"δte in development fo€"©r PTSD. Our most advanced candidate is→ε™ TNX-102 SL, which is in Ph∞✘>ase 3 development. We are also developing붣 TNX-601 which is entering a Phase 1 <→↕≤trial imminently. TNX-1600 is in the pre-IN®δ®D phase of development with enco ₩ Ωuraging data from animal models of PTSD.”Fr ¥♣∑ank Bymaster, Chief Scientific Office∑Ω§£r and co-founder of TRImara↕★★n Pharma Inc. said, “TNX-₩β1600 is a novel TRI that inhibiφ✘≤ts simultaneously thφαe reuptake of three key neurotσ✔↕ransmitters: serotoni&→€±n, norepinephrine and dopamine. Each of t↓↑hese three neurotransm•₽≤☆itters plays a key mφ§odulatory role in many CNS proce₩÷sses. Inhibiting reuptake of all ∏'✔three may provide an effective trea∞£✘tment for PTSD.”According to Dr. Aloke ✘∏π♣Dutta, “We have deve☆ loped an innovative triple reuptake inhibitφ∏$or, D-578, based on a unique pyran molecul ♦βar scaffold to address the c≤∞•εurrent therapeutic needs for PTSD and other n §♥eurological disorders. Based on our ε≥preliminary data, we ≠✔™expect a pharmacological ↔ synergy from their potent modulatory effect♦δ®• on the level of monoamine neurotr↑←λansmitters in the brain which shou₩<™ld facilitate effective treatmeε nt of these disorders.”Unde≥σr the terms of the agreement, Tonix has bee★β®←n granted an exclusive €✘£license from Wayne St✔™♥≈ate University for technology and patents related↕♦"↕ to TNX-1600 and othδδ§er pyran-based compounds. Another ₩↕••member of the class, D-473, has also shown effectδ×s in a rodent model o¶§÷f depression.the 2019≈✔π Asia-pacific Pharmaceutical IP Leader Sum Ωmit will be held in Beijing on November 14-15>✘£, and will attract more than 500 industry exp§£≠↔erts from domestic and foreign pharmaceutical ★δαγcompanies, biotechnology companies, σ★ governments, associations, law firms, intellectu≠al property agents and other companies t®×o attend. 2019 Asia-paci ¥₹fic Pharmaceutical IP Leader Summi ≈t Official regi♥£©←stration and consultation channels:Co©♦ntact：AnnPhone: 021-65650305Email：Marketing↑<σ@zenseegroup.comhttp://en.zenseegroup.com/pε✘∏β/510934/ -
1225
Health Provider in Arizona€↔₩ to Pay $6M Settlement in Bre₽→ach
A Phoenix, Ariz.-based health provider has →agreed to settle a lawsuit over ↔™∑ a computer data breach that ma↕$y have compromised health and pe÷γ rsonal data of about 3 million patient∞→→§s, employees, health insurance custo♠γmers and others.The class action lawsuit a¥λ☆ gainst Banner Health stemmed from a 2016£& cyberattack that exposed the information, The ★♣<Arizona Republic reports.< φΩThe settlement, up to $6 million, i♦☆ncludes free insurance cove↑÷Ωrage for claims of up to $1 million to₩π÷♦ cover financial losses and©γ&• two years of free credit moniβ toring through Identity Guard Total, of←♠↕ficials said.When the breac✘★ §h occurred, Banner Health initially gave th♥¶★σose affected a year of free credit ••©monitoring, officials said.Those a♠®ffected would be able to file claims for up to φ↕§$500 for ordinary exγ←penses or up to $10,000 for extraordinary expe≤•nse reimbursement such as lost≤★ time at work or professio÷δ™∏nal help with identity Ωλ≥theft issues under t¶∑♦he settlement agreement, company offi >cials said.“All things con§≈sidered, this settlement coΩmpares very favorably with th§↔ose that have been approv•≠ed in other data breach cases,★γ€” said Andrew Friedman, onβ>α≠e of the lawyers representing the p>φ÷laintiffs.The settlement was granted preα♣liminary approval and is subject t>≥o final court approval April 21, official¥₹✘s said.“This is still a pending ≤ legal matter, so we are unabλ☆δ∞le to discuss details. Howeve£εβr, we are hopeful th ≠at it will be resolved ≥Ω<soon, at which time those who were impδ≈acted can learn additional inf↓σ©ormation,” provider ≤∞§spokeswoman Becky Armendariz said.Banner Heaλ ♠lth has also agreed to improve it✘σαs information security✘ε systems, officials said.“In the meantime, data₹≈↔Ω security is one of our highest prior₽₩ities and we continue to δεwork diligently to protect theε"↕ sensitive information of our patients and€★∏★ employees,” officials said.From:insu♠λrance journalOrganizer：Chinaε> Insurance Digital & ♦&AI Development 2020Web:http://en.zenseegroup.c $om/p/560573/Contact:Ann 021-65ελ♣→650305 -
0821
Moderna Receives FDA Fast Tra &ck Designation for Zika Va≠★δccine mRNA-1893
Moderna, Inc., a clinical stage biote↑®chnology company pioneering messenger RNA (mRNAα'γ£) therapeutics and vaccines to creaε≠±$te a new generation of transformatiπ♣ve medicines for patients, today announced that ÷←♦the U.S. Food and Drug Ad>♣£ministration (FDA) has granted Fast™< Track designation for its investigatiγαonal Zika vaccine (mRNA-1893) currently being ∞ε® evaluated in a Phase 1 study for the prβ∑evention of Zika virus infection in healthy adu¥©lts.Fast Track is designed to facilitate the©↑ development and expδ€edite the review of therapies and vaccin₹φes for serious conditions and fδΩ ∏ill an unmet medical need. Programs with Fas☆αt Track designation may benefit £☆∏✔from early and frequent communication with th> ¶e FDA, in addition t↕≤o a rolling submission of the marketi∏©∑∏ng application. Moderna previous↑ly received Fast Track designation f¥€$'or its methylmalonic acid☆£emia (MMA) program (mRNA-37≥✔04), which is now recruiting patie'§nts for a Phase 1/2 clinical study.“Prot×"¥ecting against Zika virus transmission £™, particularly in women during pregnancy, continu©→es to be an area of high unmet need. Fast Track ♥™βdesignation supports our belief in the clinicalσ potential of mRNA-1893 and the importance €←of developing an effe'₹ctive vaccine that can be rapi∏★dly developed and deploye≤β×d,” said Tal Zaks, M.Dσ♥☆>., Ph.D., chief medical ∏∞≈officer at Moderna. “O ∏∞ur Zika program is part of •Moderna’s broader commitment♥ to improving global public health through'≈β developing mRNA vaccines to prevent the sp÷₩φread of infectious disease Ωs.”mRNA-1893 contains a®×n mRNA sequence encoding for the struct♥&ural proteins of Zik♠ €a virus and is designed to cause✘★ cells to secrete virus-like particl♣es, mimicking the response of the cell σ↕>↕after natural infectio₹∞♦n. Preclinical data published in§• The Journal of Infectious Diseases have sβ×hown that vaccination with mRNA-1893 pro≈£tected against transmission of Zika virus du™♦©ring pregnancy in mice.1 mRNA-1893 is currently ÷&in a Phase 1 study evaluating safety,≤€ pharmacokinetics and pharmacodynamics≤→✘→ in healthy volunteers.This project has♠ε been funded in whole or in part with Federal fun∏σds from the Department of Health and Human ✘¶₩Services (HHS); Office of the Assistant Secretary☆α for Preparedness an''♦d Response; Biomedical Advanced Research and →φ®€Development Authority (BAλ÷Ω∑RDA), under Contract No. HHSO100201600029C.froΩα©πm--Pharma Focus AsiaIn recent y ♥ears, the size of the global p↑♣←☆harmaceutical market has maintained a steady g∑αrowth, with China, South Korea, India and other £↓¶<emerging markets presenting♥σ₽ a rapid growth momentum.&nb®™"♦sp;Due to the different intellectual property p¥±εolicies of different countries, the strategic ★≠layout of global intellectual p✘★roperty, the differences of ♠♦≈"pharmaceutical intellectual property policies of÷< ¶ Asia-pacific countries, the patent review pr©≤ocess, litigation procedures and Generic drug♠♥≥ patent strategy have grad•&ually become the hot spots of the pharmace ∞✔utical intellectual ★™property industry. In this context, the 2019•™∑♠ Asia-pacific Pharmaceutical IP Leader Summit wi✔₩≤γll be held in Beijing on November 14-15, aσ♣nd will attract more than 500 indust♣☆ry experts from domestic and foreign pharm∏δaceutical companies, biotechnology companies, gov↔α ←ernments, associatio γns, law firms, intelle¥αctual property agents and other companies to atte&↔¥✔nd.2019 Asia-pacific pharma IP Leader S♥•ummit Official registration€♣® and consultation channels:Contact：AnnPhone: 021-☆₹₽65650305Email：Marketing@→zenseegroup.com -
1224
AXA XL, Slice Labs, α←Microsoft to Offer Cyber Risk Management Too♥★ls
From:insurance journalAXA XL, the p&c©αε≠ and Specialty Risk Division"" of global insurer AXA, Sli§γ♠ce Labs Inc. (Slice), an on-demand iγδnsurer of cloud techn≠ology, and Microsoft will work together to >β♦≈help improve cyber health and mitigate risks "for Microsoft 365 Busines$×<εs, Office 365 Business Premium and Office 365 Bus&€ iness customers. The new relationship w♥↓☆ill give qualifying custome<↓rs discounted access to Sl★σ×∑ice on-demand, cloud-based cyber insura ☆ ©nce provided by AXA XL.Microsoft customers will →®have access to an end-tδ''¶o-end product that w"γill help them secure their env☆★ironment and give them the critical services a≥÷nd support for incident response an €₽d remediation in the event of ™£a successful cyber-a<☆>ttack. These services ar₩♣∏e all part of AXA XL’¥≤₹σs cyber insurance policy, whi<ch will be offered at discounted pricing to q∏®∑ualified customers who represent a lower insura¥γφnce risk based on a s≥γ<ecurity posture assessment that will be prov©™ided by Microsoft Secure Score.Recent ♣₩Forrester survey results found that cybers↕♠ecurity attacks are a business realitαφy for small and mid-size busiα←¥☆nesses (SMBs), with nearly half havin↔" γg had a breach withiπλn the last year. What was more&± concerning was that 27%π∞÷ of SMBs were unaware if £ ↔they’ve had a breach. One primary issue is™ €π that 58% of the SMB÷£≈s struggle to maintain basi±' ₹c cybersecurity hygiene.“This new leve★∏∏l of integration wit↕☆h Microsoft and Slice Labs reinforces the fact ™¶that insurance is no longer an after ↓♦the fact product that compani←σλes should use as a band-aid when an incident occu☆≥↑☆rs,” said John Coletti, Chief Underwriting Offi₹≠ cer, AXA XL’s cyber insurance team in North♥€'¶ America.Small business Microsoft custome≤₽✘✔rs can access AXA XL Cyber Iπnsurance offered by Slice here.S®∑←∑lice Labs is the insurance engine behind tomo§↔>rrow’s cloud-based, on-demand dε×≥igital services ecosystems for the new e£φ €conomy. Through Slice’s Insurance Cloud Serviceπδs (ICS) platform, Slice is en®✘↑abling insurers, technolog↓€≤y companies, and other service providers to bui ✔∑ld pay-as-you-go digital ®€≤insurance products protecting the insured¥ ₽♠ anytime and anywhere. Slice is licensed in the& >nbsp;US and the UK.Organizer：China InsurancΩ ÷e Digital & AI Developmσ≥ent 2020Web:http://en.zenseegroup.com/p/☆ε560573/Contact:Ann 021-6565♣↔0305
Contact Us
Zensee_Daystar onlin±•e
© 2011-2016